DCM
VIVO

Dean Capital Management’s Meridian Bioscience Inc VIVO Stock Holding History

Dean Capital Management’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-218,310
Closed -$3.01M – 81
2017
Q1 		$3.01M Buy
218,310
+88,550
+68% +$1.24M 2.07% 15
2016
Q4 		$2.3M Buy
+129,760
New +$2.28M 1.82% 22

Other funds holding VIVO

BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Dean Capital Management's VIVO Position: Q2 2017 in Review

Dean Capital Management sold out of Meridian Bioscience Inc (VIVO) in Q2 2017, closing a stake of 218,310 shares — an estimated $3.01M sold.

Dean Capital Management first reported a position in VIVO in Q4 2016 and held it in 2 quarters. The position peaked at $3.01M in Q1 2017. 170 funds tracked by Wall St. Rank hold VIVO as of Q2 2017.

  • Dean Capital Management reported no remaining Meridian Bioscience Inc position as of Q2 2017 after selling out during the quarter.
  • Dean Capital Management sold 218,310 Meridian Bioscience Inc shares in Q2 2017, an estimated $3.01M.
  • Dean Capital Management first reported a position in Meridian Bioscience Inc in Q4 2016 and held it in 2 quarters.
  • Dean Capital Management's Meridian Bioscience Inc position peaked at $3.01M in Q1 2017.
  • 170 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q2 2017.

Based on Dean Capital Management's 13F filing for Q2 2017, filed 15 Aug 2017.